Immune checkpoint inhibitorsPD-L1Triple negative breast cancerTumor infiltrating lymphocytesTumor mutational burden? 2024 Elsevier Inc.Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype, generally associated with a high risk of recurrence and poor prognosis. Our understanding of ...
免疫检查点抑制剂联合新辅助化疗治疗三阴性乳腺癌疗效的 meta 分析 A meta-analysis of the efficacy of adding immune checkpoint inhibitors to neoadjuvant chemotherapy against triple-negative breast cancer 免疫检查点抑制剂(Immune checkpoint inhibi...
Immune checkpoint Inhibitors (ICIs) are the current mainstay for TNBC treatment [10,11], and both atezolizumab and pembrolizumab have been approved for the treatment of both early and advanced TNBC [[12], [13], [14], [15]]. Despite the effectiveness of ICIs such as Programmed cell death...
The CD155/TIGIT axis has attracted considerable interest as an emerging immune checkpoint with potential applications in cancer immunotherapy. Our research focused on investigating the role of CD155/TIGIT checkpoints in the progression of triple-negative
The other thing, of course, is the idea of using immunotherapy and immune checkpoint inhibitors. We know that TNBC has activated immune cells in the primary tumor. We also know there’s emerging data for the various checkpoint inhibitors with similar findings: that there is a small but really...
(vorinostat, panobinostat, entinostat, and valproic acid) in combination with an immune checkpoint inhibitor (anti-PD-1 and anti-CTLA-4 blockades) induces apoptosis by activating the PD-1/PD-L1 pathways in TNBC cells and mice model43. Similarly, HDACi (vorinostat, panobinostat, romidepsin, and...
Heather McArthur:I suspect that this was a negative study because of the adjuvant administration at the checkpoint inhibitor. I think that it is critically important that immune modulation be applied early on in the course ...
Immune checkpoint blockade ICIs: Immune checkpoint inhibitors SLC2A1: Glucose transporter member 1 LDHA: Lactate dehydrogenase A FASN: Fatty acid synthase MFA: Metabolic flux analysis S1P: Sphingosine-1-phosphate GSSG: Oxidized glutathione UDPG: Uridine diphosphate glucose NAAG: N-acetyl-...
This transcript has been edited for clarity. A lot has changed in the management of triple-negative breast cancer. We've learned in our patients with metastatic disease that those who have PD-L1 expression really benefit from immune checkpoint inhibitors and there are many other immune checkpoint...
[to immunotherapy].We need more agents and many more approaches to target and harness the immune system. We need combination therapies and biomarkers. [Biomarkers] are very important in lung cancer. They are helping to guide which patients to treat with checkpoint inhibitors. In breast cancer, ...